Scorpion Therapeutics

Scorpion Therapeutics, Inc. is a private biotechnology company developing small molecule precision oncology therapies. Its PI3Kα inhibitor program STX-478, a once-daily oral, mutant-selective PI3Kα inhibitor, is being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. In January 2025, Eli Lilly and Company announced a definitive agreement to acquire Scorpion's PI3Kα inhibitor program STX-478.

Scorpion Therapeutics, Inc. is a private biotechnology company developing small molecule precision oncology therapies. Its STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. On January 13, 2025, Eli Lilly and Company and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478.

Private biotechnology company developing small molecule precision oncology therapies.

• STX-478

  A once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

• 2020.10.26

  Reported2020.10.26

  Scorpion Therapeutics debuts with $108 million in funding[3]Scorpion Therapeutics以1.08亿美元融资亮相fiercebiotech.com

  Scorpion Therapeutics debuted with $108 million in funding from Atlas Venture, Omega Funds, Vida Venture, Abingworth and Partners HealthCare Innovation to pursue its precision-oncology approach.

Read more

1. 1Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program | Eli Lilly and Companyinvestor.lilly.com
2. 2Scorpion Therapeutics (United States)wikidata.org
3. 3Scorpion Therapeutics以1.08亿美元融资亮相fiercebiotech.com